If you are in crisis, help is available now. Call or text 988 to reach the Suicide & Crisis Lifeline, or text HOME to 741741. If someone is in immediate danger, call 911. This site is information only and cannot provide urgent help.

kanna.clinic

Kanna alkaloids and pharmacology (mechanism, not benefit)

About this site: kanna.clinic is an educational reference operated by AdvancedCare USA Inc. It is not a clinic, does not sell kanna or any substance, does not refer patients, and is not affiliated with suppliers. This page discusses chemistry and laboratory pharmacology. It does not claim that kanna treats anxiety, depression, or any disease. Not medical advice.

Legal snapshot (U.S., as of 2026-07-21): Sceletium tortuosum is not a DEA-scheduled controlled substance (DEA scheduling); commercial U.S. products are typically dietary supplements and are not FDA-approved drugs (FDA dietary supplements).

Crisis resources (988 / text HOME to 741741 / 911) appear site-wide. This page is not crisis care.

Why mechanism language matters

Wellness marketing often jumps from “acts on serotonin” to “works like an antidepressant.” Those are different claims. In vitro binding or enzyme data describe what purified compounds or extracts do in a dish or assay. Clinical benefit requires controlled human evidence for a defined product, population, and outcome. This page stays on the mechanism side and labels evidence level carefully.

Core mesembrine-type alkaloids

Analytical work on S. tortuosum has focused on a family of mesembrine-type alkaloids. Names you will see in papers and better labels include:

  • Mesembrine
  • Mesembrenone
  • Δ7-mesembrenone (delta-7-mesembrenone; naming varies slightly by paper)
  • Related minor mesembrine-class compounds depending on the assay

Absolute amounts and ratios depend on plant genetics, growing conditions, harvest, and especially whether material was fermented/cured (Smith et al., 1996 and subsequent alkaloid-chemistry literature; analytical reviews through the 2010s–2020s, literature surveyed 2026-07-21).

Important: other Sceletium species (e.g. material mislabeled as S. tortuosum but closer to S. emarcidum in some trade reports) may lack the same characteristic profile. Identity testing is part of quality, not trivia — see standardization.

In vitro activity: serotonin reuptake and PDE4

Peer-reviewed pharmacology on a standardized Sceletium extract (often the proprietary extract studied as Zembrin®) reports:

  1. Serotonin reuptake inhibition (SRI) in vitro — mesembrine and related constituents can inhibit serotonin transporters in laboratory assays.
  2. Phosphodiesterase-4 (PDE4) inhibition in vitro — mesembrenone and related compounds have been associated with PDE4 inhibition in laboratory systems.

A widely cited in vitro characterization is Harvey et al., 2011 (pharmacology of a standardized extract). These findings explain why researchers and clinicians raise theoretical serotonergic interaction questions when people combine kanna products with SSRIs, SNRIs, MAOIs, triptans, tramadol, and other serotonergic agents — see safety and interactions.

What in vitro does not prove

StatementStatus on this site
“Mesembrine inhibits SERT in an assay”Mechanism language; evidence-level labeled
“Kanna treats major depression”Not claimed — not an FDA-approved indication; human evidence base is limited
“Same as your SSRI”False equivalence — different compounds, doses, formulations, monitoring
“Safe because natural”Not a valid inference — pharmacology can still interact with drugs

Animal and small human studies exist for defined extracts; they are not reproduced here as efficacy advertising. For the best-known extract’s human trial design (what it measured and what it did not), see standardization and Zembrin.

Fermentation shifts the alkaloid profile

Traditional kougoed preparation involves bruising and a fermentation/curing period before drying. Ethnobotanical and chemical discussions note that fermentation is associated with relative changes among mesembrine-class alkaloids (for example, shifts involving mesembrine vs mesembrenone proportions in published comparisons of fermented vs unfermented material). Exact numbers vary by study method and sample.

Practical takeaway for readers of labels:

  • “Fermented kanna” and “raw / green kanna” are not interchangeable materials.
  • A product that does not disclose fermentation status, assay method, or alkaloid totals leaves you comparing brand names rather than chemistry.

This site does not instruct how to ferment plant material at home.

Why “kanna extract” alone tells you little

Without an assay, “kanna extract 10:1” or “pure kanna” is almost content-free:

  1. Starting biomass may differ in total alkaloids.
  2. Solvent (water, ethanol, CO₂, etc.) selects different fractions.
  3. Standardization target may be total alkaloids, a single marker, or nothing disclosed.
  4. Degradation and storage can change ratios after manufacture.

Published product surveys and analytical papers have reported severalfold differences in mesembrine-class content across commercial materials sold under the same common name (analytical literature summarized in reviews; treat any single blog “ranking” as non-authoritative). For label literacy — what to look for without treating any brand as recommended — see standardization and Zembrin.

Reading research without converting it into a protocol

When you open a paper:

  1. Identify the test article — crude plant? which extract? which batch?
  2. Identify the system — receptor assay, animal model, or human RCT?
  3. Identify the outcome — binding Ki, behavioral score, cognitive task, adverse-event table?
  4. Refuse the marketing jump — a PDE4 or SRI signal is not a license to self-treat a psychiatric diagnosis.

We deliberately do not publish personal dosing schemes, titration schedules, or “stacking” guides.

Disclaimer

Educational content only. Not medical advice. No product endorsement. No disease claims. kanna.clinic does not sell substances, does not operate a clinic, and does not refer patients. Combining serotonergic products without clinician input can be dangerous; discuss medications with your own prescriber or pharmacist.

Sources / as-of: Harvey et al. 2011 (in vitro extract pharmacology); Smith et al. 1996 and later alkaloid analytical literature; Gericke ethnobotanical/pharmacology reviews; FDA dietary-supplement framework and DEA scheduling pages reviewed 2026-07-21.